US approves two gene therapies for sickle cell disease
- 09-Dec-2023
The US Food and Drug Administration (FDA) on Friday approved two gene therapies for sickle cell disease, making one of them the first treatment in the United States based on the Nobel Prize-winning CRISPR gene editing technology. Casgevy, developed by partners Vertex Pharmaceuticals and CRISPR Therapeutics, and bluebird bio’s Lyfgenia were approved for people aged […]